Krishnan Krish S sold $193K of KRYS
Krishnan Krish S (President and CEO) sold 640 shares of Krystal Biotech, Inc. (KRYS) at $302.24 ($0.19M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for patterns of repeated insider sales/buys, but a single 10b5-1 sale generally has limited predictive power for near-term price.
Market read
The disclosure provides incremental sentiment information but no new operational or financial catalyst.
What to watch
The net holdings after the sale remain large (1,474,293 shares), and the disclosure does not indicate a change in business outlook.
Background
This is an SEC Form 4 insider transaction: CEO/President and 10% owner Krishnan Krish S sold shares under a Rule 10b5-1 plan.
Ticker impact
Krystal Biotech CEO/President sold 640 shares in an open-market transaction disclosed on SEC Form 4 at $302.2367.
Likely limited near-term impact; any reaction should fade unless accompanied by other news.
The filing is an ownership-change disclosure with a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider activity.
None.
None.
Counterpoint
Because the trade is explicitly under a pre-arranged 10b5-1 plan, the market may overreact to the headline selling.
Key entities
- issuerKrystal Biotech, Inc.
Public company whose CEO/President/10% owner reported an open-market sale on Form 4.
- insiderKrishnan Krish S
President and CEO; executed the reported sale under a pre-arranged 10b5-1 plan.
